Sutent

(Sunitinib)

Phase 3Small molecule

Sunitinib is used to treat certain types of cancer, including kidney cancer and gastrointestinal tumors. It works by blocking proteins that help cancer cells grow and divide.[1] Sutent is currently being investigated across 83 indications[3], with its most advanced program in Phase 3.[1]

Sutent is one of 1466 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

381

Total Trials

Active Trials

1,465

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

AscitesActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

ParagangliomaActive, not recruiting

Pancreatic Endocrine CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Ebola Hemorrhagic FeverActive, not recruiting

LeiomyosarcomaActive, not recruiting

GliomaPreclinical

Active, not recruiting

AscitesPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2/Phase 3

Active, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Pancreatic Endocrine CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Ebola Hemorrhagic FeverPhase 1

Active, not recruiting

LeiomyosarcomaPhase 2

Active, not recruiting

Showing 10 of 83 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sutent

Pfizer

Phase 3

15 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

Prolia

Amgen

Preclinical

14 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Tricor

JJagotec

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Pancreatic Neuroendocrine Tumor

NCT05687123

Q1 2027

N/ARecruiting

Treatment

NCT05751733

Phase 2Recruiting

Trial

NCT03297606

Phase 1Recruiting

Osteosarcoma

NCT03900793

Phase 3Active, not recruiting

Renal Cell Carcinoma

NCT02811861

Q2 2027

Phase 2Active, not recruiting

Refractory Metastatic

NCT03463460

Clinical

Trials by Indication[1]

Renal Cell Carcinoma29 trials

Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT00617253·9 enrolled

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT01984242·305 enrolled

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Completed· Pfizer logo

Pfizer··NCT04033991·684 enrolled

Show 26 more trials

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 4·NCT00706706·105 enrolled

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Completed·CCASI Pharmaceuticals, Inc.·Phase 2·NCT00444314·82 enrolled

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Active, not recruiting·EExelixis·Phase 3·NCT05678673·317 enrolled

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT00520533·8 enrolled

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Completed·—·Phase 2·NCT00570882·76 enrolled

Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients

Completed·KKidney Cancer Research Bureau·Phase 1/2·NCT00891475·114 enrolled

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00480935·3 enrolled

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

Unknown status·YYamagata University·Phase 3·NCT01481870·120 enrolled

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

Withdrawn·AAndrea Harzstark·Phase 2·NCT01616186

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Completed· Pfizer logo

Pfizer··NCT00716625·1,674 enrolled

Molecular Determinants for Therapy Response on Renal Cell Carcinoma

Unknown status·HHeidelberg University·N/A·NCT02208128·4 enrolled

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03541902·32 enrolled

Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT02072031·133 enrolled

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Terminated·Vvghtpe user·Phase 2·NCT02626754·13 enrolled

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Unknown status·RRenJi Hospital·N/A·NCT05816642·500 enrolled

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 3·NCT02535351·13 enrolled

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Completed· Amgen logo

Amgen·Phase 2·NCT00853372·85 enrolled

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Completed·IImmatics Biotechnologies GmbH·Phase 3·NCT01265901·339 enrolled

A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT02688491·300 enrolled

Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma

Terminated·AAmsterdam UMC, location VUmc·Phase 2·NCT02071641·5 enrolled

SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT00089648·61 enrolled

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Active, not recruiting· Eisai logo

Eisai·Phase 3·NCT02811861·1,069 enrolled

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT00903175·471 enrolled

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Withdrawn·GGuru Sonpavde·Phase 2·NCT03035630

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01185366·73 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 3·NCT02420821·915 enrolled

Kidney Cancer22 trials

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02761057·152 enrolled

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00459875·24 enrolled

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Terminated·HHarry Drabkin·Phase 1·NCT00747305·17 enrolled

Show 19 more trials

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01243359·6 enrolled

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00499135·25 enrolled

Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Terminated·—·N/A·NCT01740154·13 enrolled

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835158·157 enrolled

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00425386·60 enrolled

Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Completed·—·Phase 2·NCT01024205·43 enrolled

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01664182·41 enrolled

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01061411·16 enrolled

Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

Completed·RRoswell Park Cancer Institute·N/A·NCT00849186·20 enrolled

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Completed·—·Phase 2·NCT01158222·37 enrolled

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00462982·8 enrolled

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

Unknown status·—·Phase 2·NCT00717587·20 enrolled

Sunitinib Malate in Treating Patients With Kidney Cancer

Completed·CCentre Antoine Lacassagne·N/A·NCT00943839·60 enrolled

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Completed·IInstitut Claudius Regaud·Phase 2·NCT00814021·21 enrolled

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00853125·10 enrolled

Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00338884·120 enrolled

Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer

Unknown status·GGruppo Italiano Carcinoma Renale·Phase 2·NCT00626509·110 enrolled

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Completed·—··NCT01026337·43 enrolled

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

Completed·—·Phase 2·NCT00459979·30 enrolled

Breast Cancer10 trials

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Unknown status·IInstitut Català d'Oncologia·Phase 1/2·NCT00931450·70 enrolled

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

Terminated·UUniversity of California, San Francisco·Phase 1/2·NCT00616122·32 enrolled

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Completed·IIndiana University·N/A·NCT00656669·23 enrolled

Show 7 more trials

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00513695·68 enrolled

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00482755·4 enrolled

Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00824538·13 enrolled

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00435409·442 enrolled

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00393939·594 enrolled

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT00417885·6 enrolled

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00373256·488 enrolled

Gastrointestinal Stromal Tumor6 trials

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT03862768·92 enrolled

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00573404·6 enrolled

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

Completed· Pfizer logo

Pfizer·Phase 2·NCT01396148·6 enrolled

Show 3 more trials

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

Completed· Pfizer logo

Pfizer·Phase 4·NCT00793871·60 enrolled

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00372567·69 enrolled

A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00457743·36 enrolled

Small Cell Lung Cancer5 trials

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00695292·37 enrolled

Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

Unknown status·TTaipei Medical University Hospital·Phase 2·NCT01019798·16 enrolled

Sunitinib Malate in Treating Patients With Small Cell Lung Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00953459·9 enrolled

Show 2 more trials

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00453154·156 enrolled

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

Completed·NNational Cancer Center, Korea·Phase 2·NCT00620347·25 enrolled

88 more indications

Prostate Cancer5 trials

Multimodality Phase II Study in Prostate Cancer

Terminated·—·Phase 2·NCT00734851·36 enrolled

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Terminated·JJohn P. Fruehauf·Phase 1/2·NCT00879619·4 enrolled

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

Completed·—·Phase 2·NCT00672594·30 enrolled

Show 2 more trials

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00631527·19 enrolled

An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00748358·50 enrolled

Liver Cancer5 trials

Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2/3·NCT01164202·78 enrolled

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00787787·41 enrolled

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00699374·1,075 enrolled

Show 2 more trials

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·SSwiss Cancer Institute·Phase 2·NCT00514228·45 enrolled

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00524316·16 enrolled

Non-Small Cell Lung Cancer4 trials

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Terminated· Roche logo

Roche·Phase 2·NCT00434226·56 enrolled

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00748163

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00698815·130 enrolled

Show 1 more trial

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01306045·647 enrolled

Gastric Cancer4 trials

Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00555672·34 enrolled

Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer

Completed·JJohannes Gutenberg University Mainz·Phase 2·NCT00411151·52 enrolled

Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00555620·76 enrolled

Show 1 more trial

An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

Completed· Pfizer logo

Pfizer·Phase 2·NCT00226811·78 enrolled

Patients With Solid Tumors3 trials

Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

Completed·AAmsterdam UMC, location VUmc·Phase 1·NCT02058901·101 enrolled

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357318·60 enrolled

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00599924·53 enrolled

Trial3 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

A Phase I Trial of Bortezomib and Sunitinib

Completed·EEmory University·Phase 1·NCT00720148·30 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Soft Tissue Sarcoma3 trials

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00400569·48 enrolled

Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma

Unknown status·AAustralasian Sarcoma Study Group·Phase 1/2·NCT00753727·26 enrolled

Sunitinib in Certain Subtypes of Soft Tissue Sarcomas

Terminated·—·Phase 2·NCT00859456·10 enrolled

Patients With Advanced Solid Tumors3 trials

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00528619·96 enrolled

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

Terminated·YYale University·Phase 1·NCT00402415·18 enrolled

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00813423·40 enrolled

Refractory Solid Tumors3 trials

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00387920·35 enrolled

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Completed·SSamsung Medical Center·N/A·NCT02450123·1 enrolled

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Completed·SSamsung Medical Center·Phase 4·NCT02691793·1 enrolled

Treatment3 trials

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Recruiting·XXiangya Hospital of Central South University·N/A·NCT05751733·258 enrolled

Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Completed· Pfizer logo

Pfizer··NCT04669366·1,205 enrolled

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Completed·ZZai Lab (Shanghai) Co., Ltd.·Phase 2·NCT04633122·108 enrolled

Thyroid Cancer2 trials

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00381641·63 enrolled

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Completed·UUniversity of Washington·Phase 2·NCT00519896·35 enrolled

Malignant Glioma2 trials

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00499473·31 enrolled

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01462695·30 enrolled

Bladder Cancer2 trials

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

Completed·—·Phase 2·NCT00526656·9 enrolled

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Terminated·—·Phase 2·NCT01118351·19 enrolled

Esophageal Cancer2 trials

Sutent + Taxol for Advanced Esophageal Cancer

Completed·HHoosier Cancer Research Network·Phase 2·NCT00730353·28 enrolled

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT00524186·23 enrolled

Colorectal Cancer2 trials

Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00631410·12 enrolled

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00668863·71 enrolled

Metastatic Renal Cell Cancer2 trials

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Completed· Pfizer logo

Pfizer·Phase 2·NCT00267748·317 enrolled

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Terminated· Roche logo

Roche·Phase 2·NCT00491738·16 enrolled

Efficacy and Safety2 trials

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00375674·674 enrolled

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00373113·482 enrolled

Pancreatic Cancer2 trials

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00462553·37 enrolled

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00397787·64 enrolled

Melanoma2 trials

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT01005472·16 enrolled

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00482911·12 enrolled

Metastatic2 trials

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00397488·78 enrolled

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Terminated·TThe Methodist Hospital Research Institute·Phase 1/2·NCT00522249·10 enrolled

Germ Cell Tumor2 trials

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00453310·10 enrolled

Sunitinib Malate in Refractory Germ Cell Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00912912·5 enrolled

Bevacizumab2 trials

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Completed· Amgen logo

Amgen·Phase 1·NCT00861419·88 enrolled

Bevacizumab in Multiple Phase I Combinations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543504·343 enrolled

Osteosarcoma2 trials

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07477457·45 enrolled

Losartan + Sunitinib in Treatment of Osteosarcoma

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT03900793·41 enrolled

Renal Cancer1 trial

Sunitinib in Metastatic Renal Cancer

Completed·IIstituto Clinico Humanitas·Phase 2·NCT01034878·25 enrolled

Mortality1 trial

OPALINE : A Study Of Morbidity And Mortality At 2 Years

Completed· Pfizer logo

Pfizer··NCT02264665·144 enrolled

Malignant Pleural Mesothelioma1 trial

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00392444·39 enrolled

Kaposi Sarcoma1 trial

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT00521092

Renal Cell Cancer1 trial

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00465179·61 enrolled

First Line Therapy1 trial

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Completed·UUNICANCER·Phase 2·NCT00541008·92 enrolled

Prostatectomy1 trial

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00329043·64 enrolled

Gastroesophageal Junction1 trial

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00891878·12 enrolled

Advanced Solid Malignancies1 trial

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Completed· Pfizer logo

Pfizer·Phase 1·NCT00732992·12 enrolled

Multiple Myeloma1 trial

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00514137·13 enrolled

Urinary Tract Cancer1 trial

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Unknown status·—·Phase 2·NCT01118039·41 enrolled

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00843037·25 enrolled

Advanced Solid Tumors1 trial

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Completed·CCogent Biosciences, Inc.·Phase 1/2·NCT02401815·51 enrolled

Advanced Cancers1 trial

Perifosine + Sunitinib Malate for Patients With Advanced Cancers

Completed·AAEterna Zentaris·Phase 1·NCT00399152·15 enrolled

Colorectal Carcinoma1 trial

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Unknown status·AAmsterdam UMC, location VUmc·Phase 2/3·NCT03909724·60 enrolled

Second-line Therapy1 trial

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer

Completed·IInstitut Curie·Phase 2·NCT00792025·80 enrolled

Metastatic Cancer1 trial

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Completed·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT00463060·47 enrolled

Cervical Cancer1 trial

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00389974·19 enrolled

Ocular Melanoma1 trial

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

Unknown status·SSan Diego Pacific Oncology & Hematology Associates·Phase 2·NCT00489944·50 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05687123·24 enrolled

Chronic Myelomonocytic Leukemia1 trial

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00451048·10 enrolled

Primary Peritoneal Cancer1 trial

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00388037·31 enrolled

Cancer1 trial

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00890747·42 enrolled

Metastatic Head and Neck Cancer1 trial

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00387335·22 enrolled

Lip1 trial

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

Terminated· Pfizer logo

Pfizer··NCT01073644·3 enrolled

Squamous Cell Carcinoma1 trial

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00906360·36 enrolled

Phase II1 trial

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00434109·39 enrolled

Metastatic Colorectal Cancer1 trial

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00806663·22 enrolled

Transitional Cell Carcinoma1 trial

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Completed·—·Phase 2·NCT01089088·63 enrolled

Leiomyosarcoma1 trial

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00378911·44 enrolled

Advanced NSCLC1 trial

Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01850147·50 enrolled

Ovarian Cancer1 trial

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00979992·35 enrolled

Endometrial Cancer1 trial

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00478426·34 enrolled

Islet Cell Tumor1 trial

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00428597·171 enrolled

Lymphoma1 trial

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00392496·19 enrolled

Safety and Efficacy1 trial

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

Completed· Pfizer logo

Pfizer··NCT00444795·520 enrolled

Myelofibrosis1 trial

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00387426·14 enrolled

Glioblastoma1 trial

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Unknown status·BBassam Abdulkarim·Phase 2·NCT02928575·45 enrolled

Brain Metastases1 trial

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

Terminated·—·Phase 2·NCT00910039·14 enrolled

Chronic Lymphocytic Leukemia1 trial

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00398112·18 enrolled

Eye Disease1 trial

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Terminated·NNational Eye Institute (NEI)·Phase 1/2·NCT00673816·2 enrolled

Ebola Virus Disease1 trial

Multiple Treatments for Ebola Virus Disease (EVD)

Unknown status·CClinical Research Management, Inc.·Phase 1/2·NCT02380625·150 enrolled

Bone Sarcoma1 trial

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled

Gemcitabine1 trial

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Terminated·NNoah Hahn, M.D.·Phase 2·NCT00859339·9 enrolled

Recurrent Sarcoma1 trial

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00474994·53 enrolled

Acute Lymphoblastic Leukemia1 trial

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Refractory Metastatic1 trial

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Active, not recruiting·DDwight Owen·Phase 2·NCT03463460·9 enrolled

GIST1 trial

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Completed· Pfizer logo

Pfizer··NCT00716820·472 enrolled

Gastroesophageal Junction Cancer1 trial

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Completed·TTony Bekaii-Saab·Phase 2·NCT00702884·25 enrolled

Nasopharyngeal Carcinoma1 trial

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Completed·NNational University Hospital, Singapore·Phase 2·NCT01309633·80 enrolled

Colon Cancer1 trial

Sunitinib and Capecitabine for First Line Colon Cancer

Terminated·GGeorgetown University·Phase 2·NCT00961571·50 enrolled

Rectal Cancer1 trial

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Withdrawn·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT00936832

Tumour1 trial

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Completed·AAB Science·Phase 2·NCT01506336·44 enrolled

Advanced Rare Tumours1 trial

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT01396408·137 enrolled

Ovarian Clear Cell Carcinoma1 trial

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Completed·—·Phase 2·NCT01824615·30 enrolled

Unresectable1 trial

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

Completed·—·Phase 1·NCT02164240·14 enrolled

Peritoneal Carcinoma1 trial

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Completed·—·Phase 2·NCT00768144·36 enrolled

Ascites1 trial

Trial of Sunitinib for Refractory Malignant Ascites

Terminated·MMilton S. Hershey Medical Center·Phase 2·NCT00796861·4 enrolled

Metastatic Melanoma1 trial

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Terminated·KKrankenhaus Nordwest·Phase 2·NCT01216657·7 enrolled

Glioma1 trial

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Unknown status·AAmsterdam UMC, location VUmc·N/A·NCT02239952·15 enrolled

Neuroendocrine Tumors1 trial

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02315625·16 enrolled

Dacarbazine1 trial

A Phase I/II Study of Sunitinib and Dacarbazine

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00496223·11 enrolled

Unspecified2 trials

A Bioequivalence Study of Sunitinib Malate Capsules.

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05800106·24 enrolled

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 381 trial records for Sunitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sunitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sunitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Macrophage Colony Stimulating Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Alpha Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Sutent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Renal Cell Carcinoma29 trials

Kidney Cancer22 trials

Breast Cancer10 trials

Gastrointestinal Stromal Tumor6 trials

Small Cell Lung Cancer5 trials

Prostate Cancer5 trials

Liver Cancer5 trials

Non-Small Cell Lung Cancer4 trials

Gastric Cancer4 trials

Patients With Solid Tumors3 trials

Trial3 trials

Soft Tissue Sarcoma3 trials

Patients With Advanced Solid Tumors3 trials

Refractory Solid Tumors3 trials

Treatment3 trials

Thyroid Cancer2 trials

Malignant Glioma2 trials

Bladder Cancer2 trials

Esophageal Cancer2 trials

Colorectal Cancer2 trials

Metastatic Renal Cell Cancer2 trials

Efficacy and Safety2 trials

Pancreatic Cancer2 trials

Melanoma2 trials

Metastatic2 trials

Germ Cell Tumor2 trials

Bevacizumab2 trials

Osteosarcoma2 trials

Renal Cancer1 trial

Mortality1 trial

Malignant Pleural Mesothelioma1 trial

Kaposi Sarcoma1 trial

Renal Cell Cancer1 trial

First Line Therapy1 trial

Prostatectomy1 trial

Gastroesophageal Junction1 trial

Advanced Solid Malignancies1 trial

Multiple Myeloma1 trial

Urinary Tract Cancer1 trial

Hepatocellular Cancer1 trial

Anaplastic Astrocytoma1 trial

Paraganglioma1 trial

Advanced Solid Tumors1 trial

Advanced Cancers1 trial

Colorectal Carcinoma1 trial

Second-line Therapy1 trial

Metastatic Cancer1 trial

Cervical Cancer1 trial

Ocular Melanoma1 trial

Pancreatic Neuroendocrine Tumor1 trial

Chronic Myelomonocytic Leukemia1 trial

Primary Peritoneal Cancer1 trial

Cancer1 trial

Metastatic Head and Neck Cancer1 trial

Lip1 trial

Squamous Cell Carcinoma1 trial

Phase II1 trial

Metastatic Colorectal Cancer1 trial

Transitional Cell Carcinoma1 trial

Leiomyosarcoma1 trial

Advanced NSCLC1 trial

Ovarian Cancer1 trial

Endometrial Cancer1 trial

Islet Cell Tumor1 trial

Lymphoma1 trial

Safety and Efficacy1 trial

Myelofibrosis1 trial

Glioblastoma1 trial

Brain Metastases1 trial

Chronic Lymphocytic Leukemia1 trial

Eye Disease1 trial

Ebola Virus Disease1 trial